Skip to main content

Self-Experiments with Psychoactive Substances: A Historical Perspective

  • Chapter
  • First Online:
New Psychoactive Substances

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 252))

Abstract

The purpose of this chapter is to highlight the rich tradition of self-experiments (SEs) with psychoactive substances carried out by scientists and therapists for more than a century. Scientifically inspired controlled SEs dominated until the end of the twentieth century, when ethical requirements minimized controlled SEs and “wild” SEs expanded particularly with the emergence of new psychoactive substances. The review focuses on laughing gas (nitrous oxide), cannabis, cocaine, hallucinogens, entactogens, and dissociative hallucinogens. This is due to the fact that substances that induce “complex” effects such as alteration of space/time experience, ego dissolution, and increased feelings and insights (e.g., hallucinogens, entactogens) represent by far the majority of SEs, whereas SEs with substances inducing “simple” effects such as euphoria, anxiolysis, dissociation, or emotional blunting (e.g., cocaine, opioids) are much rarer or even absent (e.g., benzodiazepines). Complex drug effects are much harder to describe, thus allowing SEs to fulfill a more important function.

SEs with psychoactive drugs appeared to emerge in the mid-eighteenth century, which triggered a long-standing tradition throughout the nineteenth and early twentieth century. SEs have been de facto performed for a variety of reasons, ranging from establishing scientific knowledge and gaining philosophical insights to compensating for personal deficits. Self-experimenters can be divided into two general types. Besides their scientific intentions, “exploratory” self-experimenters intend to expand awareness and insight, whereas “compensatory” self-experimenters might aim for coping with psychiatric symptoms or personality deficits. Scientific limitations of SEs are obvious when compared to double-blind, randomized, placebo-controlled trials. Whereas the former might lead to more “realistic” detailed description of subjective effects, the latter lead to more solid results in respect to objectively measurable “average” effects. Possible adverse effects of SEs were identified that resulted in loss of scientific objectivity and decreased control over substance use and addiction, development of isolation, problematic group dynamics, and “social autism.”

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

2C-B:

2-(4-Bromo-2,5-dimethoxyphenyl)ethan-1-amine

2C-E:

2-(4-Ethyl-2,5-dimethoxyphenyl)ethan-1-amine

2C-T-2:

2-[4-(Ethylsulfanyl)-2,5-dimethoxyphenyl]ethan-1-amine

2C-T-7:

2-[2,5-Dimethoxy-4-(propylsulfanyl)phenyl]ethan-1-amine

2C-T-4:

2-[2,5-Dimethoxy-4-(propan-2-ylsulfanyl)phenyl]ethan-1-amine

2C-T-21:

2-{4-[(2-Fluoroethyl)sulfanyl]-2,5-dimethoxyphenyl}ethan-1-amine

5-HO-DMT:

3-[2-(Dimethylamino)ethyl]-1H-indol-5-ol

AM-2201:

[1-(5-Fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl)methanone

LSD:

(8β)-N,N-Diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide (d-lysergic acid diethylamide)

MDA:

1-(2H-1,3-Benzodioxol-5-yl)propan-2-amine

MDE:

1-(2H-1,3-Benzodioxol-5-yl)-N-ethylpropan-2-amine

MDMA:

1-(2H-1,3-Benzodioxol-5-yl)-N-methylpropan-2-amine

MEM:

1-(4-Ethoxy-2,5-dimethoxyphenyl)propan-2-amine

MPPP:

1-Methyl-4-phenylpiperidin-4-yl propanoate

MPTP:

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

References

  • Abouchedid R, Gilks T, Dargan PI, Archer JRH, Wood DM (2018) Assessment of the availability, cost, and motivations for use over time of the new psychoactive substances-benzodiazepines diclazepam, flubromazepam, and pyrazolam-in the UK. J Med Toxicol 14:134–143

    CAS  PubMed  Google Scholar 

  • Abramson HA (ed) (1967) The use of LSD in psychotherapy and alcoholism. Bobbs-Merrill, Indianapolis

    Google Scholar 

  • Alberts L (1921) Einwirkungen des Meskalins auf komplizierte psychische Vorgänge. Dissertation, Heidelberg University, Heidelberg

    Google Scholar 

  • Alles G (1959) Subjective reactions to phenethylamine hallucinogens. In: Featherstone RM, Simon A (eds) A pharmacologic approach to the study of the mind. C.C. Thomas, Springfield, pp 238–250

    Google Scholar 

  • Altman LK (1972) Auto-experimentation – an unappreciated tradition in medical science. N Eng J Med 286:346–352

    CAS  Google Scholar 

  • Altman LK (1986) Who goes first? The story of self-experimentation in medicine. Random House, New York

    Google Scholar 

  • Ameline A, Richeval C, Gaulier JM, Raul JS, Kintz P (2018) Characterization of flunitrazolam, a new designer benzodiazepine, in oral fluid after a controlled single administration. J Anal Toxicol 42:e58–e60

    PubMed  Google Scholar 

  • Ammon G, Patterson PGR (1971) Peyote: Zwei verschiedene Ich-Erfahrungen. Dyn Psychiatr 4(Supplement 1):47–71

    Google Scholar 

  • Anderson GM, Braun G, Braun U, Nichols DE, Shulgin AT (1978) Absolute configuration and psychotomimetic activity. In: Barnett G, Trsic M, Willette R (eds) QuaSAR – quantitative structure–activity relationships. NIDA research monograph, vol 22. United States Department of Health, Education, and Welfare, Washington, pp 8–15

    Google Scholar 

  • Arnold OH, Hoff H (1953) Untersuchungen über die Wirkungsweise von Lysergsäurediäthylamid. Wien Z Nervenheilkd Grenzgeb 6:129–150

    CAS  PubMed  Google Scholar 

  • Arthur JD (2008) Peopled darkness: perceptual transformation through Salvia divinorum. iUniverse, New York

    Google Scholar 

  • Assi S, Gulyamova N, Kneller P, Osselton D (2017) The effects and toxicity of cathinones from the users’ perspectives: a qualitative study. Hum Psychopharmacol 32:e2610

    Google Scholar 

  • Auwärter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837

    PubMed  Google Scholar 

  • Baumann MH, Glennon RA, Wiley JL (2017) Neuropharmacology of new psychoactive substances (NPS). In: The science behind the headlines. Springer, Cham

    Google Scholar 

  • Becker AM (1949) Zur Psychopathologie der Lysergsäurediäthylamidwirkung. Wiener Z Nervenhk 2:402–407

    Google Scholar 

  • Beecher HK (1959) Experimentation in man. J Am Med Assoc 169:461–478

    CAS  PubMed  Google Scholar 

  • Benz E (1989) Halluzinogen-unterstützte Psychotherapie. Medical dissertation, University of Zürich, Zürich

    Google Scholar 

  • Benzenhöfer U, Passie T (2010) Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. Addiction 105:1355–1361

    PubMed  Google Scholar 

  • Beringer K (1923) Experimentelle Psychosen durch Mescalin. Z ges Neurol Psychiatr 84:426–433

    Google Scholar 

  • Beringer K (1927) Der Meskalinrausch. Springer, Berlin

    Google Scholar 

  • Beringer K (1932) Zur Klinik des Haschischrausches. Nervenarzt 5:337–342

    Google Scholar 

  • Bisbort A (2009) Beatniks: a guide to an American subculture. Greenwood, Westport

    Google Scholar 

  • Brandt SD, King LA, Evans-Brown M (2014) The new drug phenomenon. Drug Test Anal 6:587–597

    CAS  PubMed  Google Scholar 

  • Bumke O (1903) Scopolaminum hydrobromicum. Monatsschr Psychiatr Neurol 13:62–69

    Google Scholar 

  • Caldwell WV (1968) LSD psychotherapy: an exploration of psychedelic and psycholytic therapy. Grove Press, New York

    Google Scholar 

  • Calton T, Ferriter M, Huband N, Spandler H (2008) A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia. Schizophr Bull 34:181–192

    PubMed  Google Scholar 

  • Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3:619–627

    PubMed  Google Scholar 

  • Castiglioni A (1947) A history of medicine. Alfred A. Knopf, New York

    Google Scholar 

  • Cohen S (1964) The beyond within the L.S.D. story. Atheneum, New York, pp 106–111

    Google Scholar 

  • Cohen S (1967) Discussion. In: Abramson HA (ed) The use of LSD in psychotherapy. Josiah Macy, New York, p 11

    Google Scholar 

  • Condrau G (1949) Klinische Erfahrungen an Geisteskranken mit Lysergsäure-Diäthylamid. Acta Psychiatr Scand 24:9–32

    Google Scholar 

  • Crowley A ([1917] 1973) Cocaine. Level Press, San Francisco

    Google Scholar 

  • Dargan PI, Wood DM (eds) (2013) Novel psychoactive substances. Academic Press, Amsterdam

    Google Scholar 

  • Davy H (1800) Researches, chemical and philosophical: chiefly concerning nitrous oxide, or diphlogisticated nitrous air, and its respiration. J. Johnson, London

    Google Scholar 

  • Downing JJ (1965) Zihuatanejo: an experience of transpersonative living. In: Blum R (ed) Utopiates – the use and users of LSD. Tavistock Publications, London, pp 142–178

    Google Scholar 

  • Dulchinos DP (1999) Fitz Hugh Ludlow: pioneer of inner space. In: Lyttle T (ed) Psychedelics reimagined. Autonomedia, New York, pp 29–40

    Google Scholar 

  • Ellis H (1898) Mescal, a new artificial paradise. Contemp Theatr Rev 73:131–141

    Google Scholar 

  • Erowid E, Erowid F (2015) The kratom experience from firsthand reports. In: Raffa RB (ed) The chemistry and pharmacology of opioids from a non-opium source. CRC Press, Boca Raton, pp 213–244

    Google Scholar 

  • European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2015) New psychoactive substances in Europe. An update from the EU early warning system. http://www.emcdda.europa.eu/system/files/publications/65/TD0415135ENN.pdf. Accessed 1 May 2018

  • Evans-Brown M, Sedefov R (2018) Responding to new psychoactive substances in the European Union: early warning, risk assessment, and control measures. Handb Exp Pharmacol. https://doi.org/10.1007/164_2018_160

    Google Scholar 

  • Feldman HW, Agar MH, Beschner GM (eds) (1979) Angel dust. An ethnographic study of phencyclidine users. Lexington Books, Lexington

    Google Scholar 

  • Ferkel S (1954) “Hexensalben” und ihre Wirkung. Kosmos 50:414–415

    Google Scholar 

  • Fischer R (1946) Selbstbeobachtungen im Meskalinrausch. Schweiz Z Psychol 5:308–313

    CAS  Google Scholar 

  • Fränkel F, Joël E (1927) Beiträge zu einer experimentellen Psychopathologie: der Haschischrausch. Z ges Neurol Psychiatr 111:84–106

    Google Scholar 

  • Frederking W (1955) Intoxicant drugs (mescaline and lysergic acid diethylamide) in psychotherapy. J Nerv Ment Dis 121:262–266

    CAS  PubMed  Google Scholar 

  • Freud S (1884) Über Coca. Centralbl ges Ther 2:289–314

    Google Scholar 

  • Freud S (1885a) Beitrag zur Kenntnis der Coca-Wirkung. Wien Med Wochenschr 5:129–133

    Google Scholar 

  • Freud S (1885b) Zur Coca-Wirkung beim gesunden Menschen. Centralbl ges Ther 3:253–254

    Google Scholar 

  • Friedrichs H ([1940] 2009) Die Psychologie des Meskalinrausches. VWB, Berlin

    Google Scholar 

  • Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202:513–520

    PubMed  PubMed Central  Google Scholar 

  • Gonzalez D, Riba J, Bouso JC, Gomez-Jarabo G, Barbanoj MJ (2006) Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85:157–162

    PubMed  Google Scholar 

  • Grof S (1964) K problematice optických poruch v autoexperimentech s halucinogeny. Česk Psychiatr 3:173–181

    Google Scholar 

  • Grof S (1980) LSD psychotherapy. Hunter House, Pomona

    Google Scholar 

  • Guttmann (1921) Hallluzinationen und andere Folgeerscheinungen nach experimenteller Vergiftung mit Anhalonium (Mescal). Berl Klin Wochenschr 58:816–817

    Google Scholar 

  • Haldane JS (1922) Respiration. Yale University Press, New Haven

    Google Scholar 

  • Haldane JS, Smith JL (1893) The physiological effects of air ventilated by respiration. J Pathol Bacteriol 1:168–186

    Google Scholar 

  • Hearne E, Van Hout MC (2016) “Trip-sitting” in the black hole: a netnographic study of dissociation and indigenous harm reduction. J Psychoactive Drugs 48:233–242

    PubMed  Google Scholar 

  • Heffter A (1894) Über Pellote. Arch Exp Pathol Pharmakol 34:65–86

    Google Scholar 

  • Heffter A (1898) Über Pellote. Zweite Mitteilung. Arch Exp Pathol Pharmakol 40:385–429

    Google Scholar 

  • Heimann H (1952) Die Scopolaminwirkung. Karger, Basel

    Google Scholar 

  • Henderson GL (1988) Designer drugs: past history and future prospects. J Forensic Sci 33:569–575

    CAS  PubMed  Google Scholar 

  • Henderson L, Glass W (eds) (1994) LSD: still with us after all these years. Lexington Books, New York

    Google Scholar 

  • Hoffer A, Osmond H (1967) The hallucinogens. Academic Press, New York

    Google Scholar 

  • Hofmann A (1955) The history of LSD-25. Triangle 2:117–124

    Google Scholar 

  • Hofmann (1979) LSD-mein Sorgenkind. Klett-Cotta, Stuttgart

    Google Scholar 

  • Hollingshead M (1973) The man who turned on the world. Blond & Briggs, London

    Google Scholar 

  • Huppertz LM, Moosmann B, Auwärter V (2018) Flubromazolam – basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Drug Test Anal 10:206–211

    CAS  PubMed  Google Scholar 

  • Hutter M, Moosmann B, Kneisel S, Auwärter V (2013) Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism. J Mass Spectrom 48:885–894

    CAS  PubMed  Google Scholar 

  • Huxley A (1954) The doors of perception. Chatto & Windus, London

    Google Scholar 

  • Huxley A (1980) Moksha. Chatto & Windus, London

    Google Scholar 

  • James W (1882) Subjective effects of nitrous oxide. Mind 7:186–208

    Google Scholar 

  • James W (1902) The varieties of religious experience. Longmans, New York

    Google Scholar 

  • Jansen KL (2000) A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs 32:419–433

    CAS  PubMed  Google Scholar 

  • Jansen K ([2001] 2004) Ketamine: dreams and realities. MAPS, Sarasota

    Google Scholar 

  • Jansen KL, Darracot-Cankovic R (2001) The nonmedical use of ketamine, part two: a review of problem use and dependence. J Psychoactive Drugs 33:151–158

    CAS  PubMed  Google Scholar 

  • Jay M (2009) The atmosphere of heaven. Yale University Press, London

    Google Scholar 

  • Jöel E, Fränkel F (1924) Der Cocainismus. Ein Beitrag zur Geschichte und Psychopathologie der Rauschgifte. Springer, Berlin

    Google Scholar 

  • Jöel E, Fränkel F (1926) Der Haschisch-Rausch. Beiträge zu einer experimentellen Psychopathologie. Klin Wochenschr 5:1707–1709

    Google Scholar 

  • Joël E, Fränkel F (1929) Beiträge zur experimentellen Psychopathologie. Klin Wochenschr 8:549–550

    Google Scholar 

  • Kant F, Kropf E (1928) Über Selbstversuche mit Haschisch. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 129:319–338

    CAS  Google Scholar 

  • Kelly K (1999) The little book of ketamine. Ronin, Berkeley

    Google Scholar 

  • Ketchum J (2006) Chemical warfare secrets almost forgotten. Chembooks, Santa Rosa

    Google Scholar 

  • King LA (2014) New phenethylamines in Europe. Drug Test Anal 6:808–818

    CAS  PubMed  Google Scholar 

  • King LA, Kicman AT (2011) A brief history of ‘new psychoactive substances’. Drug Test Anal 3:401–403

    CAS  PubMed  Google Scholar 

  • Kintz P, Richeval C, Jamey C, Ameline A, Allorge D, Gaulier JM, Raul JS (2017) Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism. Drug Test Anal 9:1026–1033

    CAS  PubMed  Google Scholar 

  • Kirsch MM (1986) Designer drugs. CompCare Publications, Minneapolis

    Google Scholar 

  • Kjellgren A, Jonsson K (2013) Methoxetamine (MXE) – a phenomenological study of experiences induced by a “legal high” from the internet. J Psychoactive Drugs 45:276–286

    PubMed  PubMed Central  Google Scholar 

  • Kjellgren A, Soussan C (2011) Heaven and hell – a phenomenological study of recreational use of 4-HO-MET in Sweden. J Psychoactive Drugs 43:211–219

    PubMed  Google Scholar 

  • Kjellgren A, Henningsson H, Soussan C (2013) Fascination and social togetherness-discussions about spice smoking on a Swedish internet forum. Subst Abuse 7:191–198

    PubMed  PubMed Central  Google Scholar 

  • Klinke O (1889) Hyoscin bei Geisteskranken. Z Nervenheilkd Psychopathol 12:189–196

    Google Scholar 

  • Klüver H (1966) Mescal and mechanisms of hallucinations. University of Chicago Press, Chicago

    Google Scholar 

  • Klüver H (1980) Foreword. In: Schultes RE, Hofmann A (eds) The botany and chemistry of hallucinogens, 2nd edn. C.C. Thomas, Springflied, pp VII–VVX

    Google Scholar 

  • Knauer A, Maloney WJ (1913) A preliminary note on the psychic action of mescaline, with special reference to the mechanism of visual hallucinations. J Nerv Ment Dis 40:425–436

    Google Scholar 

  • Konrad E (1888) Zur physiologischen und therapeutischen Wirkung des Hyoscinum hydrochloricum. Centralbl Nervenheilk 11:529

    Google Scholar 

  • Langston JW (2017) The MPTP story. J Parkinsons Dis 7:S11–S22

    PubMed  PubMed Central  Google Scholar 

  • Leary T (1966) Programmed communication during experiences with DMT (dimethyltryptamine). Psychedelic Rev 8:83–95

    Google Scholar 

  • Leary T, Litwin GH, Metzner R (1963) Reactions to psilocybin administered in a supportive environment. J Nerv Ment Dis 137:561–573

    CAS  PubMed  Google Scholar 

  • Lewin L (1924) Phantastica. Die betäubenden und erregenden Genussmittel. Für Ärzte und Nichtärzte. Verlag von Georg Stilke, Berlin

    Google Scholar 

  • Lewin L (1888) Über Anhalonium lewinii. Arch Exp Pathol Pharmakol 24:401–411

    Google Scholar 

  • Lewin L (1998) Phantastica: a classic survey on the use and abuse of mind-altering plants. Park Street Press, Rochester

    Google Scholar 

  • Lilly JC (1972a) Programming and metaprogramming in the human biocomputer. Julian Press, New York

    Google Scholar 

  • Lilly JC (1972b) The center of the cyclone. Julian Press, New York

    Google Scholar 

  • Lilly JC (1978) The scientist. Crown Publishers, New York

    Google Scholar 

  • Ludlow F (1857) The Hasheesh eater. Harper & Bros, New York

    Google Scholar 

  • Mantegazza P (1859 [1973]) Sulle virtu igienische e medicale de la coca. Ann univers di medic Bd. 167:449ff. Partially reprinted. In: Andrews G, Solomon D (eds) The coca leaf and cocaine papers. Harcourt Brace Jovanovich, New York, pp 38–42

    Google Scholar 

  • Maqueda AE, Valle M, Addy PH, Antonijoan RM, Puntes M, Coimbra J, Ballester MR, Garrido M, Gonzalez M, Claramunt J, Barker S, Johnson MW, Griffiths RR, Riba J (2015) Salvinorin-A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans. Int J Neuropsychopharmacol 18:pyv065

    PubMed  PubMed Central  Google Scholar 

  • Matussek N (1952) Wahnsymptome im Meskalinrausch. Medical dissertation, Max-Planck-Institut für Psychiatrie, München

    Google Scholar 

  • Mayer-Gross W, McAdam W, Walker JW (1951) Psychological and biochemical effects of lysergic acid diethylamide. Nature 168:827–828

    CAS  PubMed  Google Scholar 

  • McGlothlin W, Cohen S, McGlothlin MS (1967) Long lasting effects of LSD on normals. Arch Gen Psychiatry 17:521–532

    CAS  PubMed  Google Scholar 

  • McKenna T (1991) The archaic revival. Speculations on psychedelic mushrooms, the amazon, virtual reality, UFOs, evolution, shamanism, the rebirth of the goddess, and the end of history. Harper Collins, San Francisco

    Google Scholar 

  • Meyer P (1993) Apparent communication with discarnate entities related to DMT. Psychedelic Monogr Essays 6:29–67

    Google Scholar 

  • Meyer MR (2018) Toxicokinetics of NPS: update 2017. Handb Exp Pharmacol. https://doi.org/10.1007/1164_2018_1102

  • Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25:439–452

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B, Michel Y, Brewerton TD, Doblin R (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol 27:28–39

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, Holland J, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R (2018) 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 5:486–497

    PubMed  Google Scholar 

  • Moore M, Alltounian HS (1978) Journeys into the bright world. Para Research, Rockport

    Google Scholar 

  • Moosmann B, Huppertz Laura M, Hutter M, Buchwald A, Ferlaino S, Auwärter V (2013a) Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. J Mass Spectrom 48:1150–1159

    CAS  PubMed  Google Scholar 

  • Moosmann B, Hutter M, Huppertz LM, Ferlaino S, Redlingshöfer L, Auwärter V (2013b) Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic Toxicol 31:263–271

    CAS  Google Scholar 

  • Moosmann B, Bisel P, Auwärter V (2014) Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test Anal 6:757–763

    CAS  PubMed  Google Scholar 

  • Morris H, Wallach J (2014) From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 6:614–632

    CAS  PubMed  Google Scholar 

  • Mosher L (1999) Lecture on Soteria treatment for psychotic patients. Hannover Medical School, Hannover

    Google Scholar 

  • Nichols DE (2016) Psychedelics. Pharmacol Rev 68:264–355

    CAS  PubMed  PubMed Central  Google Scholar 

  • Novak SJ (1997) LSD before Leary. Sidney Cohen’s critique of 1950s psychedelic drug research. Isis 88:87–110

    CAS  PubMed  Google Scholar 

  • Osmond H (1970) Peyote night. In: Aaronson BS, Osmond H (eds) Psychedelics. The Hogarth Press, London, pp 67–86

    Google Scholar 

  • Oss OT, Oeric ON (1976) Psilocybin – magic mushroom grower’s guide. And/Or Press, Berkeley

    Google Scholar 

  • Ott J (1994) Ayahuasca analogues–Pangean entheogens. Natural Products, Washington

    Google Scholar 

  • Ott J (1999) Pharmahuasca: human pharmacology of oral DMT plus harmine. J Psychoactive Drugs 31:171–177

    CAS  PubMed  Google Scholar 

  • Ott J (2001a) Shamanic snuffs or entheogenic errhines. Entheobotanica, Solothurn

    Google Scholar 

  • Ott J (2001b) Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J Psychoactive Drugs 33:273–281

    CAS  PubMed  Google Scholar 

  • Ott J (2001c) Pharmepéna-psychonautics: human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine. J Psychoactive Drugs 33:403–407

    CAS  PubMed  Google Scholar 

  • Passie T (1997) Hanscarl Leuner: pioneer of hallucinogen research and psycholytic therapy. Multidiscipl Assoc Psychedelic Stud Bull 7:46–49

    Google Scholar 

  • Passie T (2002) Protocol for a research study of psilocybin in a clinical setting. Hannover Medical School, Hannover

    Google Scholar 

  • Passie T (2005) Meskalin in Deutschland 1912–1945: Grundlagenforschung, Selbstversuche und Missbrauch. In: Pieper W (ed) Nazis on speed, vol 2, pp 234–244

    Google Scholar 

  • Passie T (2018) The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985). Drug Sci Policy Law 4:1–19

    Google Scholar 

  • Passie T, Benzenhöfer U (2016) The history of MDMA as an underground drug in the United States, 1960–1979. J Psychoactive Drugs 48:67–75

    PubMed  Google Scholar 

  • Passie T, Benzenhöfer U (2018) MDA, MDMA and other “mescaline-like” substances in the US military’s search for a truth drug (1940s to 1960s). Drug Test Anal 10:72–80

    CAS  PubMed  Google Scholar 

  • Pickering GW (1949) The place of experimental method in medicine. Proc R Soc Med 42:229–234

    CAS  PubMed  PubMed Central  Google Scholar 

  • Prentiss DW, Morgan FP (1895) Anhalonium lewinii (Mescal buttons): a study of the drug with special reference to its physiological action upon man with report of experiments. Therapeut Gaz 19:577–585

    Google Scholar 

  • Prinzhorn H (1927) Erdentrückte Seele. Leuchter 8:277–296

    Google Scholar 

  • Prinzhorn H (1928) Entrückung durch Rauschgift. Zeitsch Parapsychol 55:24–34

    Google Scholar 

  • Resnikoff C (2018) Mail to Torsten Passie. 6 Apr 2018

    Google Scholar 

  • Ring FW (1887) Cocaine and its fascinations, from a personal experience. Medical Record, September 3, 1887. In: Andrews G, Solomon D (eds) The coca leaf and cocaine papers, vol 1973. Harcourt Brace Jovanovich, New York, pp 253–258

    Google Scholar 

  • Roubíček J (1961) Experimentální psychosy. SZdN, Prague

    Google Scholar 

  • Shedlin M, Wallechinski D, Sayler S (eds) ([1973] 1992) Laughing gas. Ronin, Berkeley

    Google Scholar 

  • Shulgin AT (1975) Centrally active phenethylamines. Psychopharmacol Commun 1:93–98

    CAS  PubMed  Google Scholar 

  • Shulgin A, Shulgin A (1991) PIHKAL. Transform Press, Berkeley

    Google Scholar 

  • Shulgin A, Shulgin A (1997) TIHKAL. Transform Press, Berkeley

    Google Scholar 

  • Shulgin AT, Shulgin LA, Jacob PA (1986) A protocol for the evaluation of new psychoactive drugs. Methods Find Exp Clin Pharmacol 8:313–320

    CAS  PubMed  Google Scholar 

  • Siebert DJ (1994) Salvia divinorum and Salvinorin A – new pharmacological findings. J Ethnopharmacol 43:53–56

    CAS  PubMed  Google Scholar 

  • Simpson ESC, Weiner JA (eds) (1989) The Oxford encyclopaedic English dictionary. Clarendon Press, Oxford

    Google Scholar 

  • Solms H (1956) Relationships between chemical structure and psychoses with the use of psychotoxic substances. “Comparative pharmacopsychiatric analysis”: a new research method. J Clin Exp Psychopathol 17:429–433

    CAS  PubMed  Google Scholar 

  • Solomon D (1964) Editor’s preface. In: Solomon D (ed) LSD – the consciousness-expanding drug. Putnam’s, New York, pp IX–IX

    Google Scholar 

  • Soussan C, Kjellgren A (2014) Harm reduction and knowledge exchange – a qualitative analysis of drug-related internet discussion forums. Harm Red J 11:25–33

    Google Scholar 

  • Soussan C, Kjellgren A (2015) “Chasing the high” – experiences of ethylphenidate as described on international internet forums. Subst Abuse 9:9–16

    CAS  PubMed  PubMed Central  Google Scholar 

  • Soussan C, Andersson M, Kjellgren A (2018) The diverse reasons for using novel psychoactive substances – a qualitative study of the users’ own perspectives. Int J Drug Policy 52:71–78

    PubMed  Google Scholar 

  • Stafford P (1990) Magic grams: investigations into psychedelic consciousness with Dr. Oscar Janiger. Psychedelic Monogr Essays 5

    Google Scholar 

  • Stolaroff M (1994) Thanatos to Eros: thirty-five years of psychedelic exploration. VWB, Berlin

    Google Scholar 

  • Stolaroff M (2004) The secret chief revealed. MAPS, Sarasota

    Google Scholar 

  • Stoll WA (1947) Lysergsäure-diäthylamid, ein Phantastikum aus der Mutterkorngruppe. Schweiz Arch Neurol Psychiat 60:279–280

    Google Scholar 

  • Styk J (1994) Rückblick auf die letzten sieben Jahre der Schweizerischen Ärztegesellschaft für Psycholytische Therapie (SÄPT). In: Dittrich A, Hofmann A, Leuner H (eds) Welten des Bewusstseins, vol 4. VWB, Berlin, pp 149–154

    Google Scholar 

  • Swogger MT, Hart E, Erowid F, Erowid E, Trabold N, Yee K, Parkhurst KA, Priddy BM, Walsh Z (2015) Experiences of Kratom users: a qualitative analysis. J Psychoactive Drugs 47:360–367

    PubMed  Google Scholar 

  • Szára S (1957) The comparison of the psychotic effect of tryptamine derivatives with the effects of mescaline and LSD-25 in self-experiments. In: Garattini S, Ghetti V (eds) Psychotropic drugs. Elsevier, Amsterdam, pp 460–467

    Google Scholar 

  • Szára S (1961) Hallucinogenic effects and metabolism of tryptamine derivatives in man. Fed Proc 20:885–888

    Google Scholar 

  • Tettey JNA, Crean C, Ifeagwu SC, Raithelhuber M (2018) Emergence, diversity and control of new psychoactive substances – a global perspective. Handb Exp Pharmacol. https://doi.org/10.1007/164_2018_XXX

  • Trachsel D (2011) Psychedelische chemie. Nachtschatten Verlag, Solothurn

    Google Scholar 

  • Trachsel D (2012) Fluorine in psychedelic phenethylamines. Drug Test Anal 4:577–590

    CAS  PubMed  Google Scholar 

  • Trachsel D, Lehmann D, Enzensperger C (2013) Phenethylamine: Von der Struktur zur Funktion. Nachtschatten Verlag, Solothurn

    Google Scholar 

  • Turner DM (1996) Salvinorin – the psychedelic essence of Salvia divinorum. Panther Press, San Francisco

    Google Scholar 

  • United Nations Office on Drugs and Crime (UNODC) (2018) Understanding the synthetic drug market: the NPS factor. https://www.unodc.org/documents/scientific/Global_Smart_Update_2018_Vol.19.pdf. Accessed 29 May 2018

  • Valdes LJ, Diaz JL, Paul AG (1982) Ethnopharmacology of Ska Maria Pastora (Salvia divinorum Epling and Jativa-M.). J Ethnopharmacol 7:287–312

    Google Scholar 

  • Van Dusen W (1961) LSD and the enlightenment of Zen. Psychologia 4:11–16

    Google Scholar 

  • Van Hout MC (2014) An internet study of user’s experiences of the synthetic cathinone 4-methylethcathinone (4-MEC). J Psychoactive Drugs 46:273–286

    PubMed  Google Scholar 

  • Van Hout MC, Hearne E (2015a) “Plant or poison”: a netnographic study of recreational use of 1,3-dimethylamylamine (DMAA). Int J Drug Policy 26:1279–1281

    PubMed  Google Scholar 

  • Van Hout MC, Hearne E (2015b) “Word of mouse”: indigenous harm reduction and online consumerism of the synthetic compound methoxphenidine. J Psychoactive Drugs 47:30–41

    PubMed  Google Scholar 

  • Wagmann L, Maurer HH (2018) Bioanalytical methods for new psychoactive substances. Handb Exp Pharmacol. https://doi.org/10.1007/1164_2017_1083

  • Waser PG (1990) Psychiatrie, psychopharmaka und drogen in Zürich. Kommissionsverlag Beer AG, Zürich

    Google Scholar 

  • Wasson RG (1962) Salvia divinorum – a new psychotropic drug from the mint family. Bot Mus Leafl Harvard Univ 20:77–84

    Google Scholar 

  • Weil A (1976) MDA – the love drug. J Psychedelic Drugs 8:335–337

    Google Scholar 

  • Weil A (1980) The marriage of the sun and the moon. Houghton Mifflin, Boston

    Google Scholar 

  • Weir Mitchell S (1896) Remarks on the effects of Anhelonium lewinii (the mescal button). Br Med J 2:1625–1629

    PubMed Central  Google Scholar 

  • Wellen BJ (1986) Zur Geschichte des Bilsenkrautes. Dissertation, Fachbereich Pharmazie Philipps-Universität Marburg, Marburg

    Google Scholar 

  • Weyl B (1951) Versuch einer psychopathologischen analyse der LSD-Wirkung. Medical dissertation, Albert-Ludwig-University Freiburg, Freiburg im Breisgau

    Google Scholar 

  • Widmer S (1997) Ins Herz der Dinge Lauschen, 2nd edn. Nachtschatten, Solothurn

    Google Scholar 

  • Winkler P, Csémy L (2014) Self-experimentations with psychedelics among mental health professionals: LSD in the former Czechoslovakia. J Psychoactive Drugs 46:11–19

    PubMed  Google Scholar 

  • Wood HC Jr (1869) On the medical activity of the hemp plant as grown in North America. Proc Am Philos Soc 11:226–232

    Google Scholar 

  • Zucker K (1926) Die pharmakologische Betrachtungsweise als Forschungsmethode in der Neurologie und Psychiatrie. Klin Wochenschr 5:1977–1779

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Torsten Passie .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Passie, T., Brandt, S.D. (2018). Self-Experiments with Psychoactive Substances: A Historical Perspective. In: Maurer, H., Brandt, S. (eds) New Psychoactive Substances . Handbook of Experimental Pharmacology, vol 252. Springer, Cham. https://doi.org/10.1007/164_2018_177

Download citation

Publish with us

Policies and ethics